NCT00856271View on ClinicalTrials.gov

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 28, 2005

Study Completion Date

April 30, 2005

Conditions
Essential Hypertension
Interventions
DRUG

olmesartan medoxomil

oral tablets, once daily for 8 weeks

DRUG

losartan potassium

capsules, once daily for 8 weeks

Trial Locations (5)

Unknown

Beijing

Chongqing

Guangzhou

Nanjing

Shanghai

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
collaborator

Shanghai Sankyo Pharmaceuticals Co., Ltd.

UNKNOWN

lead

Daiichi Sankyo

INDUSTRY

NCT00856271 - Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension | Biotech Hunter | Biotech Hunter